Thanks for the great analysis—one clear disagreement
“Although there has been some global response to AMR” seems like a huge underplaying of the global response over the last 20 years. Hundreds of millions (if not billions) of dollars have been poured into research into both identifying resistance patterns and new antibiotics. Powerful AI is already successfully inventing new medications Many countries (like England, Australia, New Zealand) have successfully embarked on campaigns to reduce unnecessary prescription which have massively decreased use. Donor funded public health campaigns have (largely unsuccessfully) tried to reduce prescription in places like my home here in Uganda.
Every doctor I know considers AMR almost every day in their daily practise.
AMR is extremely important, but I think its a big call to consider the issue neglected. That’s not saying though that their aren’t sub-areas within AMR research or action which are somewhat neglected that we might be able to cost-effectively intervene in.
The existing and current efforts are substantial, no doubt, but in a relative sense, AMR is neglected. Relative to the global burden of disease and expenditure on R&D, or relative to the projected costs of mitigation.
Thanks for the great analysis—one clear disagreement
“Although there has been some global response to AMR” seems like a huge underplaying of the global response over the last 20 years. Hundreds of millions (if not billions) of dollars have been poured into research into both identifying resistance patterns and new antibiotics. Powerful AI is already successfully inventing new medications Many countries (like England, Australia, New Zealand) have successfully embarked on campaigns to reduce unnecessary prescription which have massively decreased use. Donor funded public health campaigns have (largely unsuccessfully) tried to reduce prescription in places like my home here in Uganda.
Every doctor I know considers AMR almost every day in their daily practise.
AMR is extremely important, but I think its a big call to consider the issue neglected. That’s not saying though that their aren’t sub-areas within AMR research or action which are somewhat neglected that we might be able to cost-effectively intervene in.
The existing and current efforts are substantial, no doubt, but in a relative sense, AMR is neglected. Relative to the global burden of disease and expenditure on R&D, or relative to the projected costs of mitigation.